Vanadium(IV)-diamine complex with hypoglycemic activity and a reduction in testicular atrophy

Lima, Lidiane Mâcedo Alves de; Belian, Mônica F.; Silva, Wagner E.; Postal, Kahoana; Kostenkova, Kateryna; Crans, Debbie C.; Rossiter, Ana Katharyne F.F.; Júnior, Valdemiro Amaro da Silva

doi:10.1016/j.jinorgbio.2020.111312

Cited by 14 publications

(7 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the 1970s, several oxidovanadium complexes have been discussed as insulin-enhancer agents with beneficial effects on glucose and lipid metabolism, in vitro and in vivo [ 1 , 2 , 3 , 4 , 5 , 6 , 28 , 29 , 30 , 31 ]. Among the various animal models of diabetes, the most widely used for vanadium compounds is streptozotocin (STZ) induced [ 32 , 33 , 34 , 35 , 36 ]. However, the STZ-induced DM model more closely resembles type I diabetes, and type II diabetes corresponds to around 95% of the cases.…”

Section: Discussionmentioning

confidence: 99%

Dexamethasone-Induced Insulin Resistance Attenuation by Oral Sulfur–Oxidovanadium(IV) Complex Treatment in Mice

Batista,

Lima,

Gomes

et al. 2024

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

Vanadium compounds are known to exert insulin-enhancing activity, normalize elevated blood glucose levels in diabetic subjects, and show significant activity in models of insulin resistance (IR). Faced with insulin resistance, the present work investigates the antidiabetic performance of a known oxidovanadium(IV)-based coordination compound—[VIVO(octd)]—and effects associated with glucocorticoid-induced insulin resistance in mice. The effects of [VIVO(octd)] were evaluated in a female Swiss mice model of insulin resistance induced by seven days of dexamethasone treatment in comparison with groups receiving metformin treatment. Biological assays such as hematological, TyG index, hepatic lipids, glycogen, oxidative stress in the liver, and oral glucose tolerance tests were evaluated. [VIVO(octd)] was characterized with 51V NMR, infrared spectroscopy (FTIR), electron paramagnetic resonance (EPR), electronic absorption spectroscopy, and mass spectrometry (ESI–FT–MS). The [VIVO(octd)] oral treatment (50 mg/kg) had an antioxidant effect, reducing 50% of fast blood glucose (p < 0.05) and 25% of the TyG index, which is used to estimate insulin resistance (p < 0.05), compared with the non-treated group. The oxidovanadium–sulfur compound is a promising antihyperglycemic therapeutic, including in cases aggravated by insulin resistance induced by glucocorticoid treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Dexamethasone-Induced Insulin Resistance Attenuation by Oral Sulfur–Oxidovanadium(IV) Complex Treatment in Mice

Batista,

Lima,

Gomes

et al. 2024

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

show abstract

“…The applied dosage of vanadium complex is in accordance with the literature. [ 25–27 ] Body weights and tail vein blood concentrations of all animals were taken and measured on 0, 1, and 12 experimental days. The methodology of this part of the study was presented in previous research by Yanardag et al, 2009.…”

Section: Methodsmentioning

confidence: 99%

Protective effects of N(1)‐2,4‐dihydroxybenzylidene‐N(4)‐2‐hydroxybenzylidene‐S‐methyl‐thiosemicarbazidato‐oxovanadium (IV) on oxidative brain injury in streptozotocin‐induced diabetic rats

Tunalı

Bal‐Demirci

Ülküseven

et al. 2022

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Diabetes is usually accompanied by increased production of free radicals or impaired antioxidant defenses. The brain is a target tissue of the oxidative attacks caused by diabetes, and there are observed changes in the biochemical parameters of this tissue in the hyperglycemic state. In this study, we aimed to show the effect of N(1)‐2,4‐dihydroxybenzylidene‐N(4)‐2‐hydroxybenzylidene‐S‐methyl‐thiosemicarbazidato‐oxovanadium (IV) (VOL) compound on diabetic damaged brain tissue, induced by streptozotocin (STZ) on 3.0–3.5‐month‐old male rats. Single dose of STZ at 65 mg/kg was used to make rats diabetic. Four groups were created randomly. Group (i): control (intact) animals; Group (ii): VOL given control animals; Group (iii): STZ‐induced diabetic animals; and Group (iv): orally VOL administered STZ‐induced diabetic rats. VOL (0.2 mM/kg/day) administration to control and diabetic animals was performed for a period of 12 days. At the end of day 12, the brain tissues were taken and homogenized. The clear supernatants were used for the determination of glutathione (GSH), lipid peroxidation (LPO), nonenzymatic glycosylation (NEG), and protein levels. Alanine and aspartate transaminases and acetylcholinesterase (AChE), myeloperoxidase (MPO), xanthine oxidase (XO), and oxidative stress marker enzymes activities were also estimated from the homogenates. According to the obtained results, there is found significant elevation of MDA and NEG levels and activities of transaminases, MPO and XO; whereas the GSH content and the activities of AChE and antioxidant enzymes were strongly decreased in the STZ‐induced diabetic brain tissues in comparison to control group animals. Twelve days of administration of VOL complex to the diabetic animals reversed all biochemical parameters significantly in diabetic brain tissues. Our findings suggest that the VOL complex may be an ideal candidate to be used as an anti diabetic agent to improve oxidative injury and protect the brain tissue against damage caused by diabetes. This healing effect of the VOL complex may be due to its antioxidant activity and the insulin‐mimetic effects of vanadium.

show abstract

“…The interest in this type of complexes has increased, as shown by the growing number of publications since 2009 [90], and several complexes of vanadium with potential for the treatment of DM have been developed and tested in animal models showing similar effects, but less toxic features or non-observable adverse effects. Vanadium(IV)-diamine complex, shows hypoglycemic activity and a reduction in testicular atrophy [91]; [Bis(2,2,6,6-tetra methyl-3,5-heptanedione)(imidazol)oxovanadium(IV)], VO(BHED) (( 16), Figure 3) reduces serum glucose levels in animals and behave as inhibitors to suppress the overexpression of PTP-1B enzyme. [Bis(2,2,6,6-tetra methyl-3,5-heptanedione)(imidazol)oxovanadium(IV)], 4-imi, ((17), Figure 3) reduces serum glucose levels in animals and behave as inhibitors to suppress the overexpression of PTP-1B enzyme [92].…”

Section: Vanadium Therapy: Studies In Animal Modelsmentioning

confidence: 99%

Vanadium Compounds with Antidiabetic Potential

Amaral,

Moniz,

Silva

et al. 2023

IJMS

View full text Add to dashboard Cite

Over the last four decades, vanadium compounds have been extensively studied as potential antidiabetic drugs. With the present review, we aim at presenting a general overview of the most promising compounds and the main results obtained with in vivo studies, reported from 1899–2023. The chemistry of vanadium is explored, discussing the importance of the structure and biochemistry of vanadate and the impact of its similarity with phosphate on the antidiabetic effect. The spectroscopic characterization of vanadium compounds is discussed, particularly magnetic resonance methodologies, emphasizing its relevance for understanding species activity, speciation, and interaction with biological membranes. Finally, the most relevant studies regarding the use of vanadium compounds to treat diabetes are summarized, considering both animal models and human clinical trials. An overview of the main hypotheses explaining the biological activity of these compounds is presented, particularly the most accepted pathway involving vanadium interaction with phosphatase and kinase enzymes involved in the insulin signaling cascade. From our point of view, the major discoveries regarding the pharmacological action of this family of compounds are not yet fully understood. Thus, we still believe that vanadium presents the potential to help in metabolic control and the clinical management of diabetes, either as an insulin-like drug or as an insulin adjuvant. We look forward to the next forty years of research in this field, aiming to discover a vanadium compound with the desired therapeutic properties.

show abstract

Vanadium(IV)-diamine complex with hypoglycemic activity and a reduction in testicular atrophy

Cited by 14 publications

References 73 publications

Dexamethasone-Induced Insulin Resistance Attenuation by Oral Sulfur–Oxidovanadium(IV) Complex Treatment in Mice

Dexamethasone-Induced Insulin Resistance Attenuation by Oral Sulfur–Oxidovanadium(IV) Complex Treatment in Mice

Protective effects of N(1)‐2,4‐dihydroxybenzylidene‐N(4)‐2‐hydroxybenzylidene‐S‐methyl‐thiosemicarbazidato‐oxovanadium (IV) on oxidative brain injury in streptozotocin‐induced diabetic rats

Vanadium Compounds with Antidiabetic Potential

Contact Info

Product

Resources

About